You are here

FDA Rejects Expanded Indication for Nivolumab (Opdivo)

Agency asks for additional data in BRAF-mutated patient population

The FDA has issued a complete response letter (CRL) regarding the supplemental biologics license application (sBLA) for nivolumab (Opdivo, Bristol-Myers Squibb) as a single agent for the treatment of previously untreated patients, specifically those with BRAF V600 mutation-positive unresectable or metastatic melanoma.

As part of the CRL, the FDA indicated the need for additional data in the BRAF-mutated patient population.

The sBLA submitted for nivolumab as a single agent for previously untreated metastatic melanoma was based on clinical data from the phase 3 CheckMate-066 trial, which evaluated nivolumab in treatment-naïve patients with BRAF wild-type advanced melanoma compared with dacarbazine. The FDA approved nivolumab as a single agent for the treatment of patients with BRAF wild-type unresectable or metastatic melanoma, based on results from the CheckMate-066 trial, on November 15. In addition to data from this study, Bristol-Myers Squibb submitted findings for nivolumab in BRAF V600 mutation-positive metastatic melanoma, which was the subject of the FDA’s CRL.

A separate sBLA, which included data from the CheckMate-067 trial evaluating nivolumab as a single agent and in combination with ipilimumab (Yervoy, Bristol-Myers Squibb) in patients with previously untreated advanced melanoma, was accepted by the FDA for review in September and was granted Priority Review with a target action date of January 23, 2016. Data for nivolumab monotherapy in both BRAF wild-type and BRAF V600 mutation-positive advanced melanoma was included as part of this application.

Source: Bristol-Myers Squibb, November 27, 2015



Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks